Docetaxel Combined with Celecoxib in Neoadjuvant Breast Cancer Therapy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
COX-2 Expression as Prognostic Biomarker
- February 15, 2019
- Reading time: 1 minute
On January 31, 2019, the Journal of Clinical Oncology published exploratory analysis from the REMAGUS02 Phase III trial examining the relationship between COX-2 inhibition via celecoxib and COX-2 gene expression (PTGS2) in locally advanced HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.
Trial Design
Among 156 locally advanced, COX-2-expressing HER2-negative breast cancer patients:
Group 1: Epirubicin plus cyclophosphamide (standard regimen) followed by Docetaxel plus Celecoxib
Group 2: Epirubicin plus cyclophosphamide followed by Docetaxel monotherapy
Stratification: age, menopausal status, TNM classification, hormone receptor status
Key Findings
COX-2 Low-Expression Subgroup:
- Concurrent docetaxel plus celecoxib resulted in reduced event-free survival and overall survival
COX-2 High-Expression Subgroup:
- No significant impact of celecoxib addition
Clinical Significance
Results demonstrate that COX-2 expression status serves as a predictive biomarker for celecoxib efficacy in breast cancer neoadjuvant therapy. Patient stratification by COX-2 expression may optimize therapeutic outcomes and minimize unnecessary toxicity.
Data Source
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. Journal of Clinical Oncology, Published online January 31, 2019.
Clinical Note: Treatment decisions require consultation with oncology specialists regarding individual biomarker status and therapeutic optimization.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1